cell
key
mediat
immun
monitor
antigenspecif
cell
becom
central
progress
mani
field
medic
research
includ
infecti
diseas
vaccinolog
transplant
allergi
autoimmun
tumor
immunolog
among
techniqu
avail
measur
cell
immun
elispot
found
wide
use
simpl
reliabl
sensit
quantit
effici
cell
util
elispot
technolog
permit
enumer
individu
antigenspecif
cell
detect
secretori
product
antigentrigg
releas
interferon
gamma
contrast
supernatantbas
assay
elisa
cytokin
bead
arraysluminex
analyt
directli
captur
around
secret
cell
evad
detect
bind
receptor
adjac
cell
dilut
supernat
degrad
proteas
gener
limit
detect
pbmc
elispot
order
magnitud
sensit
supernatantbas
measur
use
similar
approach
antigenspecif
cell
also
detect
flow
cytometri
intracytoplasm
cytokin
stain
ic
typic
ic
less
sensit
detect
rare
cell
howev
due
detect
limit
furthermor
elispot
assay
detect
actual
secret
analyt
pharmacolog
untreat
cell
ic
account
post
transcript
regul
requir
treatment
cell
golgi
inhibitor
prevent
secret
initi
elispot
assay
found
wide
use
detect
cell
continu
advanc
elispot
field
enabl
detect
cytolyt
regulatori
cell
via
measur
antigeninduc
releas
granzym
b
perforin
respect
come
detect
polyfunct
cell
dual
color
elispot
assay
permit
measur
cytokin
coexpress
individu
cell
sensit
ic
howev
low
frequenc
respons
difficult
detect
ic
readili
detect
dual
color
elispot
year
less
success
experiment
homemad
dual
color
elispot
assay
kit
recent
becom
readili
avail
advanc
larg
increas
versatil
elispot
assay
allow
monitor
major
cell
effector
lineag
requir
pbmc
per
data
point
elispot
need
less
pbmc
flow
cytometrybas
assay
import
context
clinic
trial
number
pbmc
obtain
critic
limit
factor
coupl
eas
valid
implement
elispot
made
one
primari
assay
choic
immun
monitor
fact
antigenspecif
cell
given
specif
frequent
occur
low
frequenc
pbmc
continu
major
challeng
immun
monitor
particularli
true
chronic
infect
long
term
immun
memori
auto
tumorreact
cell
immun
respons
induc
subunit
vaccin
set
antigenspecif
cell
occur
detect
limit
even
elispot
assay
therefor
one
major
goal
immun
monitor
lower
detect
limit
elispot
assay
antigenspecif
cell
toward
goal
report
overnight
rest
cryopreserv
pbmc
thaw
util
elispot
assay
would
increas
sensit
assay
provid
higher
antigeninduc
spot
count
promis
hold
rest
strategi
readili
embrac
recommend
immun
monitor
panel
rest
howev
come
cost
substanti
addit
work
longer
assay
durat
loss
pbmc
limit
clinic
trial
assum
rest
period
apoptot
pbmc
contain
within
thaw
pbmc
die
leav
higher
frequenc
viabl
function
cell
assay
rational
hold
clinic
pbmc
sampl
frequenc
apoptot
cell
high
also
hold
pbmc
frozen
accord
optim
protocol
number
apoptot
cell
neglig
current
systemat
studi
exist
compar
benefit
vs
downsid
overnight
rest
studi
report
design
fill
gap
immun
monitor
gener
elispot
particular
aim
establish
accur
frequenc
antigenspecif
cell
vivo
ideal
cell
assay
perform
freshli
isol
pbmc
soon
possibl
blood
draw
h
durat
elispot
assay
antigen
stimul
result
signific
vitro
expans
antigenspecif
cell
therefor
frequenc
measur
freshli
isol
cell
match
sought
vivo
frequenc
test
result
obtain
freshli
isol
pbmc
therefor
consid
baselin
variat
pbmc
handl
cryopreserv
rest
compar
pbmc
cryopreserv
thaw
accord
protocol
establish
frequenc
measur
freshli
isol
pbmc
ex
vivo
thaw
pbmc
shown
ident
cell
establish
pbmc
cryopreserv
without
loss
cell
function
notabl
equal
perform
noncryopreserv
ex
vivo
cryopreserv
pbmc
seen
without
rest
cell
plate
assay
right
thaw
present
studi
select
cef
peptid
stimul
cell
mump
antigen
stimul
cell
cef
pool
consist
immunodomin
peptid
cytomegalo
epstein
barr
flu
viru
figur
b
show
cell
separ
experi
confirm
cef
peptid
activ
mump
antigen
activ
cell
respect
figur
also
show
cef
mumpsantigenelicit
cell
recal
respons
similar
spot
count
obtain
noncryopreserv
pbmc
test
ex
vivo
within
h
blood
draw
freezethaw
without
rest
paper
refer
nonrest
freezethaw
cell
fresh
distinguish
rest
ex
vivo
pbmc
extens
subsequ
studi
confirm
multitud
antigen
recal
memori
cell
noncryopreserv
ex
vivo
pbmc
freezethaw
pbmc
without
rest
fresh
provid
compar
result
shown
thaw
pbmc
number
apoptot
cell
less
measur
within
minut
thaw
basic
assumpt
paper
therefor
freshli
thaw
nonrest
fresh
pbmc
show
equal
perform
noncryopreserv
ex
vivo
pbmc
use
test
impact
rest
elispot
basic
question
address
therefor
overnight
rest
reliabl
improv
elispot
assay
perform
rel
test
result
obtain
freshli
thaw
pbmc
cryopreserv
pbmc
twenti
five
donor
randomli
select
epbmc
donor
librari
provid
cellular
technolog
limit
ctl
shaker
height
oh
usa
pbmc
obtain
healthi
donor
leucapheresi
cell
donor
frozen
hundr
ident
aliquot
allow
replic
experi
use
cell
materi
hundr
hlatyp
immun
character
donor
constitut
librari
pbmc
test
fresh
reactiv
cef
peptid
pool
mump
antigen
antigen
respons
level
rang
undetect
defin
differ
spot
count
triplic
medium
control
well
vs
triplic
antigenstimul
well
significantli
differ
base
ttest
evalu
high
reach
antigenelicit
spot
form
unit
sfu
per
one
million
pbmc
background
typic
zero
sampl
exceed
spot
per
million
background
neglig
low
pbmc
sampl
test
fresh
rest
graphic
represent
data
paper
omit
background
spot
wide
rang
recal
respons
level
individu
antigen
within
differ
human
donor
typic
seen
noncryopreserv
pbmc
ex
vivo
even
donor
vaccin
time
test
given
time
point
vaccin
even
characterist
recal
respons
inbr
mice
paramet
immun
genet
background
environment
influenc
kept
constant
individu
donor
respons
level
cef
mump
link
donor
display
high
respons
level
cef
could
low
nonrespond
mump
vice
versa
exampl
shown
figur
addit
donor
low
nonrespond
antigen
respond
vigor
other
antigen
pbmc
test
see
epbmc
data
base
epbmc
librari
consist
larg
select
precharacter
pbmc
sampl
establish
hla
type
antigen
reactiv
therefor
low
respons
level
detect
either
cef
peptid
mump
antigen
reflect
low
frequenc
cef
mump
antigenreact
cell
respect
pbmc
donor
gener
lack
function
particular
pbmc
sampl
caus
suboptim
freez
storag
thaw
cell
antigenspecif
cell
frequent
occur
low
frequenc
rang
rest
pbmc
perform
hope
improv
signaltonois
perform
pbmc
sampl
show
weak
reactiv
antigen
select
antigeninduc
sfu
per
one
million
pbmc
cutoff
low
high
respond
statu
shown
figur
base
sfu
measur
use
freshli
thaw
pbmc
donor
qualifi
low
respond
cef
peptid
pool
pbmc
donor
thaw
split
two
batch
one
batch
plate
elispot
assay
within
h
thaw
fresh
batch
incub
h
plate
elispot
assay
rest
show
figur
six
donor
display
slightli
approxim
two
fold
elev
cefinduc
spot
count
rest
five
donor
spot
count
decreas
equal
overal
differ
cef
peptideinduc
sfu
fresh
rest
pbmc
signific
among
low
respond
evalu
wilcoxon
signedrank
test
pvalu
consid
signific
wilcoxon
test
nonparametr
statist
hypothesi
test
use
compar
two
sampl
pair
differ
test
twelv
twenti
five
donor
qualifi
low
respond
mump
antigen
reactiv
use
sfu
per
million
pbmc
cutoff
criterion
figur
low
respond
pbmc
five
donor
show
slightli
increas
approxim
twofold
spot
count
rest
seven
show
decreas
spot
count
rest
also
mump
antigeninduc
sfu
wilcoxon
signedrank
test
show
statist
signific
differ
fresh
rest
pbmc
mump
low
respond
also
medium
background
significantli
affect
rest
data
shown
therefor
one
would
presum
rest
pbmc
obtain
higher
signaltonois
perform
frequenc
antigenreact
cell
low
low
respond
sampl
rest
prove
provid
consist
benefit
pbmc
donor
respond
antigen
stimul
sfu
per
million
pbmc
defin
high
respond
eight
nine
cef
high
respond
rest
result
increas
sfu
count
figur
except
one
donor
increas
slightli
two
fold
increas
donor
less
two
fold
one
donor
fresh
rest
pbmc
provid
unchang
reactiv
level
overal
increas
seen
rest
reach
statist
signific
judg
wilcoxon
signedrank
test
cef
high
respond
pvalu
measur
respons
direct
mump
among
high
respond
rest
signific
benefit
figur
thirteen
mump
high
respond
three
show
approxim
twofold
increas
mumpsinduc
sfu
remain
donor
spot
count
decreas
n
similar
n
except
cef
high
respond
rest
therefor
variabl
statist
insignific
effect
pbmc
sampl
perform
elispot
assay
occasion
donor
two
fold
increas
seen
donor
compar
decreas
spot
count
observ
retest
pbmc
donor
without
rest
establish
whether
gain
loss
observ
rest
given
sampl
inher
featur
given
pbmc
sampl
whether
sampl
respond
unpredict
h
vitro
cultur
figur
result
shown
four
donor
repres
donor
first
seen
sampl
low
respond
cef
high
respond
mump
vice
versa
donor
vs
donor
donor
low
respond
cef
mump
high
respond
candida
ppd
purifi
protein
deriv
tuberculin
data
shown
second
donor
test
fresh
high
low
respond
cef
mump
first
experi
respons
level
reproduc
repeat
experi
antigen
interassay
variat
freshli
thaw
sampl
signific
third
rest
signific
gain
seen
cef
respons
first
experi
also
evid
repeat
experi
donor
rest
result
moder
gain
cef
respons
first
experi
gain
similar
magnitud
also
seen
repeat
experi
donor
similarli
decreas
mump
respons
seen
rest
donor
reproduc
repeat
experi
unchang
mump
respons
level
donor
fourth
figur
illustr
increas
one
antigen
rest
result
unchang
decreas
respons
level
anoth
antigen
fifth
figur
illustr
low
respond
categori
rest
predict
increas
reactiv
level
sinc
increas
decreas
antigen
reactiv
rest
reproduc
repeat
experi
appear
inher
propens
respect
pbmc
without
stimul
exposur
specif
growthsurviv
factor
primari
cell
die
frequent
within
short
time
cell
cultur
rest
pbmc
medium
h
repres
stimulationfre
cultur
period
differ
cell
lineag
contain
within
pbmc
also
conceiv
cellscelllineag
appear
viabl
directli
thaw
injur
freezethaw
process
undergo
apoptosi
rest
period
establish
mani
cell
lost
rest
compar
viabl
pbmc
count
within
h
thaw
pbmc
fresh
viabl
cell
recov
h
rest
period
acridin
orangeethidium
bromid
stain
use
distinguish
live
dead
cell
shown
figur
loss
seen
one
pbmc
sampl
overal
loss
occur
similar
rate
half
cell
lost
rest
diminut
seen
highli
signific
p
determin
pair
wilcoxon
signedrank
sum
test
less
half
origin
seed
pbmc
recov
rest
sever
sampl
advis
plan
experi
involv
rest
pbmc
two
three
fold
excess
pbmc
plate
assay
sinc
pbmc
limit
clinic
studi
loss
pbmc
need
consid
vs
possibl
benefit
assay
result
obtain
rest
cef
highrespond
observ
rest
sampl
increas
frequenc
antigenspecif
respons
see
figur
could
partli
explain
publish
claim
find
could
explain
preferenti
surviv
cell
pbmc
sampl
rest
period
cell
type
could
die
rapidli
lead
cell
enrich
rest
sampl
increas
respons
cef
conjunct
decreas
mump
respons
rest
eg
donor
figur
might
result
rapid
die
cell
formal
test
hypothesi
use
flow
cytometri
monitor
potenti
chang
frequenc
cell
lineag
follow
rest
phenotyp
character
freshli
thaw
rest
pbmc
flow
cytometri
show
statist
signific
chang
cell
subset
due
rest
figur
importantli
correl
exist
moder
chang
percentag
cell
given
pbmc
sampl
cef
peptideelicit
sfu
respons
similarli
slight
increasesdecreas
frequenc
cell
rest
result
proport
increasedecreas
mump
recal
respons
data
shown
chang
cell
respons
seen
rest
therefor
result
chang
cell
function
alter
cell
frequenc
within
test
sampl
spite
increas
work
load
cell
loss
rest
advoc
presum
improv
signaltonois
perform
elispot
assay
shown
rest
predict
impact
low
respond
wors
low
respond
rest
sampl
could
provid
decreas
antigeninduc
spot
count
particular
cell
eg
donor
figur
due
unpredict
outcom
rest
need
two
three
time
pbmc
accommod
cell
loss
test
hypothesi
desir
increas
signaltonois
perform
pbmc
accomplish
simpli
increas
number
freshli
thaw
pbmc
plate
elispot
assay
evalu
hypothesi
directli
plate
unrest
pbmc
twofold
serial
dilut
ask
observ
cef
mump
antigenspecif
sfu
show
linear
increas
proport
number
cell
assay
data
present
figur
suggest
million
pbmc
per
well
rang
high
degre
linear
number
pbmc
plate
observ
sfu
panel
panel
b
compart
linear
relationship
spot
count
pbmc
number
rang
cellswel
confirm
nine
independ
experi
use
differ
antigen
pbmc
differ
donor
data
shown
therefor
doubl
tripl
number
freshli
thaw
pbmc
plate
elispot
assay
one
predict
accomplish
rest
spite
increas
cell
number
need
strategi
requir
cell
rest
literatur
research
identifi
two
origin
studi
benefici
effect
rest
describ
directli
one
studi
fresh
rest
pbmc
four
patient
stage
iii
iv
follicular
lymphoma
compar
addit
bear
larg
tumor
burden
patient
chemotherapi
second
studi
data
shown
four
healthi
donor
assess
respons
cef
cmv
one
low
respond
categori
benefit
rest
seen
donor
remain
three
donor
cef
cmv
high
respond
approxim
twofold
increas
seen
two
high
respond
janetzki
et
al
also
refer
studi
kierstead
et
al
suggest
overnight
rest
essenti
achiev
optim
cell
respons
compar
unfrozen
pbmc
though
detail
comparison
experi
provid
data
list
shown
studi
anoth
report
rest
posit
correl
detect
low
frequenc
cell
studi
inconclus
rest
rest
one
sever
assay
paramet
compar
result
differ
increas
number
cell
plate
anoth
assay
paramet
result
differ
suffic
predict
improv
signal
nois
perform
assay
figur
studi
overal
studi
pbmc
donor
test
reactiv
cmv
flu
peptid
three
possess
cmvspecif
cell
five
respond
flu
peptid
result
compar
thirteen
center
elispot
analysi
perform
accord
less
differ
protocol
influenc
differ
paramet
number
posit
respons
studi
studi
present
benefit
rest
test
systemat
larger
cohort
subject
maintain
assay
paramet
constant
rest
caus
predict
gain
assay
sensit
respons
highmagnitud
alon
gain
averag
less
twofold
statist
signific
might
limit
signific
immun
diagnost
term
respons
enhanc
rest
alreadi
clearcut
without
rest
also
ad
labor
increas
need
sampl
materi
might
justifi
importantli
respons
seen
freshli
isol
noncryopreserv
pbmc
correspond
respons
seen
freshli
thaw
unrest
pbmc
figur
c
therefor
enhanc
obscur
sought
ex
vivo
frequenc
antigenreact
cell
low
magnitud
respons
reactiv
magnitud
rest
unpredict
effect
decreas
unchang
reactiv
seen
frequent
instanc
increas
reactiv
contrast
doubl
number
freshli
thaw
pbmc
predict
doubl
signaltonois
perform
elispot
assay
therefor
doubl
number
freshli
thaw
pbmc
plate
elispot
assay
one
reliabl
accomplish
accur
monitor
high
low
magnitud
respons
deriv
cell
alik
less
labor
amount
cell
materi
studi
done
pbmc
healthi
donor
cryopreserv
importantli
accord
optim
protocol
permit
full
recoveri
cell
reactiv
optim
thaw
previous
shown
confirm
figur
b
cef
mump
respons
studi
paper
envis
sever
scenario
rest
benefit
cell
monitor
rest
like
benefit
cell
monitor
number
apoptot
cell
high
thaw
sampl
number
apoptot
cell
might
high
pbmc
frozen
thaw
optim
condit
situat
rest
might
help
rescu
result
success
cell
work
attent
drawn
optim
freez
thaw
condit
follow
protocol
pbmc
healthi
donor
yield
viabl
less
apoptoticdead
cell
import
field
adopt
optim
cryopeservationthaw
condit
rest
might
also
benefici
pbmc
subject
certain
diseas
receiv
medicationtreat
increas
apoptosi
cell
apc
pbmc
patient
stage
iii
iv
follicular
lymphoma
addit
receiv
chemotherapi
like
fall
categori
furthermor
number
apoptot
cell
elev
sampl
ship
suboptim
condit
requir
long
transit
period
store
suboptim
condit
freez
experi
human
pbmc
never
chill
ship
heparin
full
blood
process
wash
warm
apoptot
cell
present
pbmc
signific
number
still
aliv
stain
count
live
cell
dead
time
function
assay
perform
therefor
without
account
apoptot
cell
one
would
plate
fewer
function
pbmc
live
cell
count
suggest
frequenc
sfu
accordingli
decreas
rest
apoptot
popul
gone
rel
frequenc
function
cell
increas
subsequ
also
spot
count
apoptot
cell
select
stain
dye
jopro
therefor
support
cimt
associ
cancer
immunotherapi
suggest
includ
count
apoptot
cell
immun
monitor
routin
present
well
establish
whether
apoptot
cell
nonfunct
bystand
cell
whether
exert
inhibitori
effect
function
cell
assay
addit
passiv
adjust
count
freshli
thaw
cell
function
cell
viabl
minu
apoptot
might
accomplish
simpler
way
rest
apoptot
cell
inhibitori
howev
select
deplet
cell
rest
requir
improv
perform
pbmc
sampl
contain
signific
number
apoptot
cell
unlik
necrosi
trigger
inflamm
apoptosi
intrins
nonphlogist
process
apoptot
cell
suppress
proinflammatori
respons
neutrophil
mononuclear
phagocyt
elicit
antiinflammatori
respons
cell
activ
secret
lactoferrin
cell
undergo
apoptosi
one
key
mechan
apoptot
cell
instruct
innat
immun
system
lactoferrin
bind
receptor
phagocyt
inhibit
proinflammatori
respons
via
thu
lactoferrin
inhibit
product
proinflammatori
mediat
induc
secret
antiinflammatori
cytokin
includ
need
establish
experiment
whether
presenc
cell
undergo
apoptosi
pbmc
affect
cell
function
assay
elispot
ic
rest
might
also
benefit
cell
monitor
serum
donor
contain
immun
suppress
factor
drug
exampl
cancer
patient
hivinfect
subject
isol
donor
serum
cultur
overnight
neutral
medium
pbmc
might
recov
function
similarli
rest
might
benefit
serum
contain
cytokin
stimul
cell
innat
immun
system
produc
analyt
assay
exampl
potent
stimul
product
macrophag
nk
dendrit
cell
sever
lineag
case
background
medium
control
high
spot
produc
cell
typic
larger
spot
produc
cell
innat
immun
system
therefor
identifi
proper
gate
strategi
elispot
analysi
sever
cell
lineag
innat
system
plastic
adher
deplet
rest
step
result
lower
background
addit
stimulatori
effect
serum
cytokin
act
vivo
wane
rest
neutral
test
medium
vitro
cryopreserv
human
pbmc
donor
acquir
librari
pbmc
epbmc
offer
cellular
technolog
ltd
ctl
shaker
height
oh
usa
addit
highresolut
hlatyp
pbmc
previous
character
cell
reactiv
panel
antigen
differ
aliquot
pbmc
sampl
permit
exact
reproduct
reactiv
subsequ
experi
therefor
preestablish
respons
level
serv
refer
valu
also
serv
posit
control
unknown
respons
given
pbmc
sampl
measur
polyclon
stimul
seb
pha
also
serv
refer
standardposit
control
measur
antigenspecif
cell
respons
protein
peptid
recal
antigen
provid
relev
refer
valu
also
spot
morpholog
induc
polyclon
stimul
fundament
differ
spot
elicit
antigen
prior
test
pbmc
cryovial
store
liquid
vapor
phase
transfer
dri
ice
styrofoam
contain
transport
short
term
storag
laboratori
cell
thaw
follow
protocol
establish
provid
optim
recoveri
function
cryopreserv
pbmc
specif
rapidli
warm
cryovial
place
minut
bead
bath
cryovial
invert
twice
resuspend
cell
ml
cell
suspens
contain
cryovial
million
cell
gentli
aspir
util
widebor
ml
pipett
transfer
ml
v
bottom
falcon
tube
recov
residu
cell
cryovial
rins
ad
ml
warm
ctl
antiaggreg
medium
contain
benzonas
addit
ml
ctl
antiaggreg
medium
ad
ml
tube
rate
ml
per
second
wash
aliquot
pbmc
count
fluoresc
microscopi
use
acridin
orang
ethidium
bromid
aoeb
stain
live
dead
cell
respect
apoptot
cell
stain
jopro
invitrogen
count
similarli
pbmc
wash
twice
ml
medium
resuspend
final
concentr
pbmcml
medium
test
freshli
thaw
pbmc
refer
cell
fresh
paper
cell
plate
onto
elispot
assay
plate
within
h
thaw
rest
cell
incub
h
concentr
cellsml
ctltest
medium
wash
twice
ctltest
medium
readjust
cellsml
medium
plate
elispot
assay
human
immunospot
kit
obtain
ctl
assay
perform
accord
manufactur
recommend
pvdf
membran
prewet
ethanol
requir
recommend
kit
antigen
cef
peptid
pool
mump
antigen
biowhittak
walkersvil
md
usa
lot
dilut
plate
first
triplic
captur
antibodi
precoat
assay
plate
final
volum
per
antigen
dissolv
ctl
test
medium
also
constitut
negativemedium
control
plate
contain
antigen
medium
control
store
incub
cell
readi
plate
thaw
pbmc
adjust
ctl
test
medium
million
pbmcml
cellswel
plate
per
well
use
widebor
pipett
tip
plate
gentli
tap
side
ensur
even
distribut
cell
settl
incub
h
incub
follow
complet
elispot
protocol
plate
air
dri
laminar
flow
hood
prior
analysi
elispot
plate
scan
analyz
use
immunospot
core
reader
ctl
spot
form
unit
sfu
automat
calcul
immunospot
softwar
antigen
stimul
condit
medium
neg
control
use
function
data
present
mean
sfu
per
pbmc
induc
specifi
antigen
minu
sfu
count
neg
control
experi
neg
control
less
sfu
per
pbmc
total
cell
subset
assess
flow
cytometri
briefli
cell
stain
ml
falcon
roundbottom
tube
human
clone
clone
clone
bd
bioscienc
san
jose
ca
usa
fix
formaldehyd
minimum
event
acquir
use
bd
facscanto
iii
bd
analyz
facsdivatm
version
softwar
bd
relationship
sfu
cell
number
test
linear
regress
comparison
match
pre
postthaw
sfu
test
twotail
nonparametr
wilcoxon
signedrank
test
pvalu
less
twotail
consid
signific
data
clearli
show
rest
univers
applic
approach
improv
perform
cryopreserv
pbmc
detect
low
frequenc
cell
respons
contrast
consid
half
cell
lost
rest
one
reliabl
doubl
signal
nois
perform
cell
assay
doubl
number
freshli
thaw
cell
plate
assay
use
amount
cell
rest
would
requir
doubl
cell
number
possibl
conveni
accur
measur
cell
respons
rest
might
benefici
special
clinic
condit
data
present
suggest
clearli
advantag
accur
monitor
immun
respons
among
healthi
subject
might
precis
sampl
deriv
mani
diseas
state
unpredict
increas
decreas
cell
reactiv
rest
rel
cell
frequenc
ex
vivo
potenti
miss
posit
respons
due
substanti
cell
loss
ad
labor
complex
protocol
investig
well
advis
establish
whether
rest
inde
benefit
immun
monitor
particular
studi
popul
